-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
-
-
-
-
-
-
-
FDA accepts Ionis olezarsen application for priority review
-
-
-
-
-
-
-
Ionis reports positive HAE treatment switch study results
-
-
-
-
-
-
-
Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel
-
-
-
-
-
-
-
Ionis reports second quarter 2024 financial results
-
-
-
-
-
-
-
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
-
15,557 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

